Published in Nature on March 18, 2010
MicroOrganoSphere Drug Screen Pilot Trial in Colorectal Cancer (CRC) | NCT05189171
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 6.05
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell (2015) 2.94
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol (2011) 2.69
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 2.15
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 2.15
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J (2012) 2.09
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell (2014) 1.88
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood (2014) 1.81
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol (2014) 1.76
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell (2015) 1.71
Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell (2013) 1.67
Principles and strategies for developing network models in cancer. Cell (2011) 1.65
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 1.60
Allosteric activation of functionally asymmetric RAF kinase dimers. Cell (2013) 1.60
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov (2012) 1.57
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Retracted An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol (2014) 1.54
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A (2015) 1.51
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Mol Cell (2015) 1.47
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol (2014) 1.47
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife (2015) 1.46
Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases. Chem Biol (2014) 1.46
Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J Biol Chem (2010) 1.45
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci U S A (2011) 1.44
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol (2014) 1.44
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell (2014) 1.43
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology (2012) 1.43
Protein kinase signaling networks in cancer. Curr Opin Genet Dev (2010) 1.41
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol (2014) 1.40
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol (2011) 1.37
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Signalling scaffolds and local organization of cellular behaviour. Nat Rev Mol Cell Biol (2015) 1.35
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol (2006) 4.84
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res (2001) 4.20
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol (2009) 3.37
Ras signaling and therapies. Adv Cancer Res (2009) 2.93
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell (2009) 2.82
Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A (1998) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res (1999) 1.40
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 3.70
The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov (2014) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Selective amygdalohippocampectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy: a meta-analysis of comparative studies. J Neurosurg (2013) 2.71
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol (2004) 2.66
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37